List of Excipients in Branded Drug ERIVEDGE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Genentech Inc	ERIVEDGE	vismodegib	50242-140	CELLULOSE, MICROCRYSTALLINE	2028-11-11
Genentech Inc	ERIVEDGE	vismodegib	50242-140	FERRIC OXIDE RED	2028-11-11
Genentech Inc	ERIVEDGE	vismodegib	50242-140	FERROSOFERRIC OXIDE	2028-11-11

Erivedge Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Erivedge (vismodegib) is an oral small-molecule capsule marketed by Genentech, a Roche company, for adults with metastatic basal cell carcinoma or locally advanced basal cell carcinoma that has recurred after surgery or is unsuitable for surgery or radiation.[1] The commercial opportunity is not a biosimilar program. It is a generic or differentiated oral-solid-dose strategy focused on excipient equivalence, capsule quality, supply resilience, patient tolerability, and potential reformulation.

The current product uses a conventional hard-gelatin capsule and a relatively simple excipient system. That reduces manufacturing complexity but leaves opportunities in lactose management, dissolution control, capsule-shell optimization, packaging, and lifecycle reformulation.

What is Erivedge and how is it formulated?

Erivedge contains 150 mg of vismodegib in an oral hard capsule. Vismodegib is a Hedgehog pathway inhibitor that binds Smoothened, a transmembrane protein in the Hedgehog signaling pathway.[1]

Erivedge dosage-form profile

Attribute	Erivedge profile
Active ingredient	Vismodegib
Strength	150 mg
Route	Oral
Dosage form	Hard gelatin capsule
Therapeutic class	Hedgehog pathway inhibitor
Initial U.S. approval	January 30, 2012
U.S. application	NDA 203388
Manufacturer	Genentech, Inc., a Roche company
Main indications	Metastatic or locally advanced basal cell carcinoma
Administration	One capsule orally once daily, with or without food
Key safety issue	Embryo-fetal toxicity; pregnancy prevention requirements
Biosimilar exposure	None; vismodegib is a small molecule

The FDA label identifies lactose monohydrate, sodium lauryl sulfate, povidone, croscarmellose sodium, and magnesium stearate as capsule-fill excipients. The capsule shell contains gelatin, titanium dioxide, and colorants. The product also uses pharmaceutical printing ink.[1]

The formulation is consistent with a wet- or dry-granulated immediate-release capsule designed to disperse a poorly water-soluble active pharmaceutical ingredient. Sodium lauryl sulfate can improve wetting, while povidone supports granule or particle binding. Croscarmellose sodium promotes disintegration, and magnesium stearate controls lubrication during encapsulation.

What excipient functions are most important in Erivedge?

The central formulation challenge is balancing vismodegib’s physicochemical properties with rapid, reproducible release from a relatively high-dose capsule.

Lactose monohydrate

Lactose is likely the principal diluent and contributes to powder bulk, flow, and capsule-fill consistency. It also creates a commercial constraint for patients with lactose intolerance and for manufacturers seeking a lactose-free version.

A generic developer could evaluate mannitol, microcrystalline cellulose, dibasic calcium phosphate, or spray-dried lactose as alternatives. Any substitution would require comparative dissolution, content uniformity, stability, and impurity assessment.

Lactose replacement has the strongest commercial logic when it delivers a clear product claim:

• lactose-free formulation;
• improved moisture control;
• reduced supplier concentration;
• better powder flow;
• improved compatibility with automated encapsulation.

A simple lactose substitution is unlikely to command a premium by itself. It becomes commercially relevant when combined with a patient-access or manufacturing benefit.

Sodium lauryl sulfate

Sodium lauryl sulfate is a surfactant used to improve wetting and dispersion of hydrophobic drug particles. It can improve dissolution robustness, but its concentration must be controlled carefully. Excess surfactant can affect powder properties, capsule compatibility, gastrointestinal tolerability, and dissolution sensitivity.

Potential alternatives include polysorbates, sodium docusate, poloxamers, or specialized wetting systems. These materials require careful review because surfactant substitution can alter:

• dissolution across pH conditions;
• precipitation after dispersion;
• impurity formation;
• capsule-shell interaction;
• gastrointestinal tolerability;
• analytical method performance.

A lower-surfactant formulation with equivalent dissolution could reduce excipient cost and improve tolerability, but it would need a strong comparative package.

Povidone

Povidone supports binding and can improve granule integrity. Its molecular weight and concentration affect granulation behavior, residual moisture, dissolution, and manufacturability.

Commercially attractive work could focus on replacing povidone with copovidone, hydroxypropyl cellulose, or another low-moisture binder. The objective would be a formulation with:

• lower process water demand;
• shorter drying time;
• lower residual solvent or moisture risk;
• improved scale-up performance;
• reduced variability in granule strength.

Croscarmellose sodium

Croscarmellose sodium is a superdisintegrant. Its particle size, grade, distribution, and incorporation method can materially affect capsule disintegration and dissolution.

A generic formulation can use crospovidone or sodium starch glycolate as alternatives, but the choice must account for the drug’s particle size and surfactant system. Crospovidone may provide strong wicking and rapid disintegration; sodium starch glycolate may produce substantial swelling. Either could change the dissolution profile or create sensitivity to compression or granulation conditions.

Magnesium stearate

Magnesium stearate reduces friction during manufacture. Over-lubrication can slow wetting and dissolution, particularly when the active is poorly soluble. Control of blending time, lubricant concentration, and shear is therefore important.

A formulation using sodium stearyl fumarate or another lubricant could offer improved dissolution robustness. The commercial value is strongest if the alternative lubricant permits shorter blending or reduces batch-to-batch dissolution variability.

What formulation patents protect Erivedge?

Erivedge is a small-molecule product, so its intellectual-property exposure differs from a biologic. There is no biosimilar pathway. Any competitive product would generally proceed through the abbreviated new drug application pathway, subject to patent certifications and regulatory exclusivity.

The relevant patent categories include:

1. Composition-of-matter patents covering vismodegib or related Hedgehog inhibitors.
2. Pharmaceutical-composition patents covering vismodegib with defined excipients or physical properties.
3. Manufacturing patents covering crystallization, particle-size control, purification, or formulation processes.
4. Method-of-use patents covering treatment of basal cell carcinoma and other Hedgehog-driven conditions.
5. Regulatory exclusivity associated with the NDA and any pediatric or orphan-drug protections.

The commercial importance of an excipient strategy depends on whether the reference formulation is protected by a composition patent, whether the generic can design around any formulation claims, and whether the FDA Orange Book contains relevant listed patents. The Orange Book is the controlling source for current listed-patent and exclusivity information.[2]

No biosimilar litigation risk applies because vismodegib is not a biologic. The principal entry risks are small-molecule patent litigation, Paragraph IV certifications, regulatory exclusivity, and the ability to demonstrate pharmaceutical equivalence.

When does Erivedge lose exclusivity?

Erivedge’s core U.S. regulatory and patent timing must be evaluated separately.

FDA approval occurred in 2012. New chemical entity exclusivity generally lasts five years from approval, subject to the statutory framework and any applicable patent challenge timing. Orphan-drug exclusivity may apply to the approved orphan indication for seven years from approval under the Orphan Drug Act.[3]

Patent expiration dates cannot be inferred solely from the approval date. U.S. patent terms generally run 20 years from the earliest effective nonprovisional filing date, with possible patent-term adjustment and, for eligible patents, patent-term extension.[4] A reliable entry assessment therefore requires review of the current Orange Book, relevant patent family members, terminal disclaimers, and any litigation or settlement agreements.

For commercial planning, the key timing scenarios are:

Scenario	Commercial implication
Core composition patent remains enforceable	Generic entry may require a Paragraph IV challenge or delayed launch
Only formulation or method patents remain	A design-around or label carve-out may be possible
Regulatory exclusivity has expired but patents remain	ANDA approval may proceed only subject to patent resolution
Patents and exclusivity have expired	Competitive generic launch becomes more feasible
Patent settlement limits launch	Actual entry may occur later than nominal patent expiry

What excipient strategies could support a generic Erivedge?

Strategy 1: Reference-matched formulation

The lowest regulatory-risk route is to reproduce the qualitative excipient composition where practical and match the reference product’s critical quality attributes.

Advantages include:

• lower formulation-development risk;
• simpler pharmaceutical-equivalence analysis;
• fewer excipient-justification issues;
• easier dissolution bridging;
• reduced risk of unexpected food-effect differences.

The disadvantages are dependence on the reference product’s excipient supply chain and limited differentiation.

Strategy 2: Lactose-free capsule

A lactose-free product could replace lactose with mannitol, microcrystalline cellulose, or another suitable diluent. The opportunity is commercially credible because it addresses a recognizable patient concern and may broaden use among patients who avoid lactose-containing medicines.

The principal risks are altered powder density, capsule-fill weight, drug distribution, and dissolution. A lactose-free formulation may also require new process parameters and a different capsule size.

Strategy 3: Low-surfactant or surfactant-free formulation

Reducing sodium lauryl sulfate could improve label simplicity and potentially tolerability. This is technically more difficult because the surfactant may be important to dissolution.

Possible approaches include:

• reducing drug particle size;
• increasing specific surface area;
• using a wetting polymer;
• applying a lipid or polymer dispersion;
• using a co-processed excipient;
• optimizing the active-to-diluent ratio.

A surfactant-free product is commercially interesting but carries greater bioequivalence and scale-up risk than a reference-matched formulation.

Strategy 4: Manufacturing-resilient formulation

The strongest near-term opportunity may be a formulation designed for reliable production rather than patient-facing differentiation.

Relevant design targets include:

• reduced blend segregation;
• low sensitivity to lubricant mixing time;
• robust capsule-fill weight;
• controlled electrostatic behavior;
• reduced moisture uptake;
• improved stability under temperature cycling;
• fewer critical process parameters.

These improvements can reduce manufacturing cost and supply interruptions without changing the label claim.

Strategy 5: Modified-release or alternative oral delivery

A modified-release version is technically possible but commercially difficult. Erivedge is administered once daily, so controlled release offers limited convenience benefit. A new delivery system would likely require more extensive clinical and regulatory development.

Potential uses could include reducing peak-related adverse effects, but the benefit must justify formulation complexity and clinical risk. This is less attractive than an immediate-release generic or a lactose-free capsule.

What FDA regulatory pathway applies to Erivedge generics?

A generic developer would normally pursue an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The product would need to demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.[5]

For Erivedge, the development package would typically address:

• same active ingredient and strength;
• same dosage form and route;
• equivalent labeling, subject to permitted carve-outs;
• comparative dissolution;
• bioequivalence;
• inactive-ingredient suitability;
• container-closure compatibility;
• stability;
• impurity control;
• capsule appearance and identification.

A formulation with different excipients is not automatically excluded. The practical issue is whether the differences affect safety, efficacy, bioequivalence, dissolution, or product quality.

A method-of-use patent can create a label-carve-out question. If a protected indication cannot be included in the generic label, the applicant may need to omit that use while retaining nonprotected indications. The scope of any carve-out must be consistent with FDA labeling requirements and patent law.

What commercial opportunities exist beyond a generic capsule?

Regional and contract-manufacturing supply

Vismodegib is a specialized oncology product with lower expected volume than mass-market oral drugs. This can favor manufacturers with:

• flexible small-batch capability;
• containment for potent compounds;
• reliable capsule-filling systems;
• oncology-focused distribution;
• established pharmacovigilance infrastructure.

A regional supplier may compete through supply reliability rather than price alone.

Excipient supply agreements

The reference formulation depends on common excipients, but supply risk can still arise from pharmaceutical-grade manufacturing capacity, dual sourcing, and regional qualification. Suppliers can create value through:

• compendial-grade lactose and surfactant supply;
• dual-source qualification packages;
• low-endotoxin or low-bioburden grades;
• particle-size-controlled excipients;
• regulatory documentation;
• change-control support.

Lifecycle reformulation

A reformulated vismodegib product could target patients with swallowing difficulty, lactose avoidance, or intolerance of standard capsule excipients. However, the indication population is limited and the original product is already once daily. The commercial case would therefore depend on a demonstrable clinical or adherence benefit.

Combination and specialty distribution

Vismodegib is used in a specialty oncology setting. Commercial opportunities may involve distribution, patient support, adherence monitoring, and access programs rather than a new excipient alone. A formulation that reduces administration burden or improves storage conditions could support specialty-pharmacy positioning.

How does Erivedge compare with competing Hedgehog inhibitors?

Sonidegib, marketed as Odomzo, is the closest approved pharmacologic comparator in the Hedgehog pathway class. It is also an oral small molecule used for advanced basal cell carcinoma, but it has a different active ingredient, formulation, dosing profile, and safety profile.[6]

Factor	Erivedge	Odomzo
Active ingredient	Vismodegib	Sonidegib
Dosage form	Capsule	Capsule
Pathway target	Smoothened	Smoothened
Main disease area	Advanced basal cell carcinoma	Locally advanced basal cell carcinoma
Dosing	150 mg once daily	200 mg once daily
Formulation opportunity	Lactose substitution, dissolution robustness, capsule optimization	Product-specific excipient and release strategy
Biosimilar risk	None	None
Generic risk	ANDA and patent-based	ANDA and patent-based
Commercial differentiation	Tolerability, supply, access, formulation	Tolerability, dosing, access, formulation

The excipient strategy for Erivedge should not be copied directly from Odomzo. Bioequivalence is product-specific, and excipient differences can affect dissolution, absorption, and tolerability.

What generic entry risks exist for Erivedge?

The main risks are:

1. Patent uncertainty. Core, formulation, process, and use patents may expire on different dates.
2. Paragraph IV litigation. A challenger may provoke litigation if it asserts that listed patents are invalid, unenforceable, or not infringed.
3. Bioequivalence failure. Poorly controlled particle size, surfactant level, or lubrication can produce dissolution differences.
4. Limited market size. A small specialty market may support only a few suppliers.
5. Label restrictions. Carving out a patented indication may be difficult if the remaining label still implies the protected use.
6. Manufacturing containment. Potent oncology compounds require suitable occupational and environmental controls.
7. Market-access pressure. Oncology generics often face rapid price erosion after multiple entrants.
8. Reference-product supply and sampling. Comparative development depends on consistent reference-product characterization.

A formulation that is technically novel but difficult to prove bioequivalent may have less commercial value than a conventional formulation with predictable performance.

How strong is the Erivedge excipient opportunity?

The opportunity is moderate for generic development and limited for premium reformulation.

The strongest opportunities are:

• a reference-matched generic with reliable dissolution;
• a lactose-free capsule;
• a manufacturing-resilient formulation;
• dual-sourced excipient systems;
• regional supply and specialty-pharmacy distribution.

The weaker opportunities are:

• modified release, because Erivedge already uses once-daily dosing;
• major excipient replacement without a patient or manufacturing benefit;
• a premium reformulation without clinical evidence;
• a biosimilar-style development strategy, which does not apply to vismodegib.

Key Takeaways

• Erivedge is a 150 mg vismodegib hard capsule approved for advanced basal cell carcinoma.
• The labeled excipients include lactose monohydrate, sodium lauryl sulfate, povidone, croscarmellose sodium, and magnesium stearate.
• The most important technical risks are wetting, dissolution, powder flow, content uniformity, lubrication, and capsule-fill consistency.
• A lactose-free formulation is the clearest patient-facing excipient opportunity.
• A reference-matched generic is the lowest-risk regulatory strategy.
• Vismodegib has no biosimilar pathway; competitive entry relies on the ANDA and Hatch-Waxman framework.
• Current Orange Book listings, patent-family review, and litigation records determine the actual U.S. entry date.
• Modified-release reformulation has limited commercial logic because Erivedge is already administered once daily.
• Manufacturing reliability and specialty distribution may create more value than excipient novelty alone.

FAQs

Can lactose be removed from an Erivedge generic?

Yes. Lactose can potentially be replaced with another pharmaceutical diluent, but the alternative must support equivalent dissolution, content uniformity, stability, and bioequivalence.

Is sodium lauryl sulfate essential to vismodegib dissolution?

It may contribute materially to wetting and dissolution, but its necessity must be established through formulation screening and comparative dissolution testing. Removing it could create a higher bioequivalence risk.

Does Erivedge require a biosimilar application?

No. Vismodegib is a chemically synthesized small molecule. A competing product would generally use the ANDA pathway rather than the biosimilar pathway.

Can a generic Erivedge omit a patented indication?

Potentially. A permitted label carve-out may be available for a protected method of use, but the final labeling must remain consistent with FDA requirements and must not improperly encourage the patented use.

Is a pediatric formulation of vismodegib commercially attractive?

The opportunity is limited unless pediatric use expands substantially. A liquid, sprinkle, or smaller-dose formulation would require formulation, stability, dosing, and clinical justification that may not be supported by the current approved use.

References

1. U.S. Food and Drug Administration. (2024). Erivedge (vismodegib) capsules, prescribing information. Genentech, Inc.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Orphan drug designation and approval database. https://www.accessdata.fda.gov/scripts/opdob/

4. United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension information. https://www.uspto.gov/

5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

6. U.S. Food and Drug Administration. (2024). Odomzo (sonidegib) prescribing information. Sun Pharmaceutical Industries, Inc.